The results from this review support the extending body of evidence indicating that combining atezolizumab with carboplatin and nab-paclitaxel chemotherapy might have encouraging survival benefits in patients with treatment-naïve metastatic nonsquamous PD-L1-positive NSCLC, with a tolerable safety profile. The gene discussed is CD274; the disease is non-small cell lung carcinoma.